Nigel Russell


Ontology type: schema:Person     


Person Info

NAME

Nigel

SURNAME

Russell

Publications in SciGraph latest 50 shown

  • 2019-02 Targeting FLT3 mutations in AML: review of current knowledge and evidence in LEUKEMIA
  • 2018-08 High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia in BLOOD CANCER JOURNAL
  • 2017-05 Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia in LEUKEMIA
  • 2017-02 A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia in LEUKEMIA
  • 2016-12 Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial in BLOOD CANCER JOURNAL
  • 2016-09 Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide in BONE MARROW TRANSPLANTATION
  • 2016-06 Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT in BONE MARROW TRANSPLANTATION
  • 2015-06 A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia in LEUKEMIA
  • 2015-06 Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party in BONE MARROW TRANSPLANTATION
  • 2015-04 Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia in LEUKEMIA
  • 2015-02 Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation in BONE MARROW TRANSPLANTATION
  • 2015-01 Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study in BONE MARROW TRANSPLANTATION
  • 2014-01 EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT in BONE MARROW TRANSPLANTATION
  • 2014-01 Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation in BONE MARROW TRANSPLANTATION
  • 2013-12 Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells in BMC PHARMACOLOGY AND TOXICOLOGY
  • 2013-12 The acute impact of a hematopoietic allograft on lung function and inflammation: a prospective observational study in BMC PULMONARY MEDICINE
  • 2013-04 Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial in LEUKEMIA
  • 2012-12 Targeting of CD34+CD38-cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia in BMC CANCER
  • 2012-10 The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2012-04 Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation in BONE MARROW TRANSPLANTATION
  • 2011-12 P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPA in BMC CANCER
  • 2011-06 Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial in BLOOD CANCER JOURNAL
  • 2011-03-12 Susceptibility to MDS: DNA Repair and Detoxification Genes in THE MYELODYSPLASTIC SYNDROMES
  • 2011-01 Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data in BONE MARROW TRANSPLANTATION
  • 2011-01 The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation in LEUKEMIA
  • 2010-11 The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study in BONE MARROW TRANSPLANTATION
  • 2010-10 The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry in LEUKEMIA
  • 2010-05 Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission in ANNALS OF HEMATOLOGY
  • 2010-01 Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia in LEUKEMIA
  • 2009-07 Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms in BONE MARROW TRANSPLANTATION
  • 2008-07 Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment in LEUKEMIA
  • 2008-03 Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant in BONE MARROW TRANSPLANTATION
  • 2006-12 DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412 in LEUKEMIA
  • 2006-11 The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors in BONE MARROW TRANSPLANTATION
  • 2005-09 Fusion of NUP214 to ABL1 on amplified episomes in T-ALL – implications for treatment in LEUKEMIA
  • 2005-03 The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants in BONE MARROW TRANSPLANTATION
  • 2004-10 Interleukin-1β maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways in LEUKEMIA
  • 2003-01 Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia in LEUKEMIA
  • 2001-12 Naso-jejunal feeding in allogeneic bone marrow transplant recipients: results of a pilot study in BONE MARROW TRANSPLANTATION
  • 2001-06 Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant in BONE MARROW TRANSPLANTATION
  • 2001-03 Successful engraftment of a second transplant using non-myeloablative conditioning as treatment for graft failure following unrelated donor BMT in BONE MARROW TRANSPLANTATION
  • 2000-11 High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support in BONE MARROW TRANSPLANTATION
  • 2000-10 The Effect of Bcr-Abl Protein Tyrosine Kinase on Maturation and Proliferation of Primitive Haematopoietic Cells in MOLECULAR MEDICINE
  • 2000-09 Rapid onset retinopathy in a diabetic patient following bone marrow transplantation in BONE MARROW TRANSPLANTATION
  • 2000-02 The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia in BONE MARROW TRANSPLANTATION
  • 1999-10 Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin’s lymphomas and Hodgkin’s disease in BONE MARROW TRANSPLANTATION
  • 1999-09 P-glycoprotein expression is associated with resistance to spontaneous in vitro apoptosis in AML in LEUKEMIA
  • 1999-04 Low incidence of human herpesvirus 8 in stem cell collections from myeloma patients in BONE MARROW TRANSPLANTATION
  • 1998-11 Stem cell mobilisation in lymphoproliferative diseases in BONE MARROW TRANSPLANTATION
  • 1998-11 Blast maturity and CD34 expression determine the effects of the differentiating agents KH1060 and 9-cis-retinoic acid on the differentiation and clonogenicity of non-M3 acute myeloid leukaemia cells in LEUKEMIA
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.240404.6", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419248.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417893.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.273109.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415970.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415172.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.439749.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.11835.3e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.426108.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.459389.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419319.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10025.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10392.39", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5600.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415598.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415490.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412920.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413449.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413396.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412914.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413964.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.265892.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5645.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411339.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.475435.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.6292.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410345.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417581.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4563.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7700.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417068.c", 
            "type": "Organization"
          }
        ], 
        "familyName": "Russell", 
        "givenName": "Nigel", 
        "id": "sg:person.0675233407.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675233407.23"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:45", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_499.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0675233407.23'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0675233407.23'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0675233407.23'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0675233407.23'


     

    This table displays all metadata directly associated to this object as RDF triples.

    78 TRIPLES      10 PREDICATES      42 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.0675233407.23 schema:affiliation N2575e3fe81ec4631b14aec2a1d5262f9
    2 https://www.grid.ac/institutes/grid.10025.36
    3 https://www.grid.ac/institutes/grid.10392.39
    4 https://www.grid.ac/institutes/grid.11835.3e
    5 https://www.grid.ac/institutes/grid.265892.2
    6 https://www.grid.ac/institutes/grid.273109.e
    7 https://www.grid.ac/institutes/grid.410345.7
    8 https://www.grid.ac/institutes/grid.410569.f
    9 https://www.grid.ac/institutes/grid.411339.d
    10 https://www.grid.ac/institutes/grid.412914.b
    11 https://www.grid.ac/institutes/grid.412920.c
    12 https://www.grid.ac/institutes/grid.413396.a
    13 https://www.grid.ac/institutes/grid.413449.f
    14 https://www.grid.ac/institutes/grid.413964.d
    15 https://www.grid.ac/institutes/grid.415172.4
    16 https://www.grid.ac/institutes/grid.415490.d
    17 https://www.grid.ac/institutes/grid.415598.4
    18 https://www.grid.ac/institutes/grid.415970.e
    19 https://www.grid.ac/institutes/grid.417068.c
    20 https://www.grid.ac/institutes/grid.417581.e
    21 https://www.grid.ac/institutes/grid.417893.0
    22 https://www.grid.ac/institutes/grid.419248.2
    23 https://www.grid.ac/institutes/grid.419319.7
    24 https://www.grid.ac/institutes/grid.426108.9
    25 https://www.grid.ac/institutes/grid.439749.4
    26 https://www.grid.ac/institutes/grid.4563.4
    27 https://www.grid.ac/institutes/grid.459389.a
    28 https://www.grid.ac/institutes/grid.475435.4
    29 https://www.grid.ac/institutes/grid.5600.3
    30 https://www.grid.ac/institutes/grid.5645.2
    31 https://www.grid.ac/institutes/grid.6292.f
    32 https://www.grid.ac/institutes/grid.7700.0
    33 schema:familyName Russell
    34 schema:givenName Nigel
    35 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675233407.23
    36 schema:sdDatePublished 2019-03-07T14:45
    37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    38 schema:sdPublisher Nf5de4e512bba4835a20bab74dfe1929e
    39 sgo:license sg:explorer/license/
    40 sgo:sdDataset persons
    41 rdf:type schema:Person
    42 N2575e3fe81ec4631b14aec2a1d5262f9 schema:affiliation https://www.grid.ac/institutes/grid.240404.6
    43 sgo:isCurrent true
    44 rdf:type schema:OrganizationRole
    45 Nf5de4e512bba4835a20bab74dfe1929e schema:name Springer Nature - SN SciGraph project
    46 rdf:type schema:Organization
    47 https://www.grid.ac/institutes/grid.10025.36 schema:Organization
    48 https://www.grid.ac/institutes/grid.10392.39 schema:Organization
    49 https://www.grid.ac/institutes/grid.11835.3e schema:Organization
    50 https://www.grid.ac/institutes/grid.240404.6 schema:Organization
    51 https://www.grid.ac/institutes/grid.265892.2 schema:Organization
    52 https://www.grid.ac/institutes/grid.273109.e schema:Organization
    53 https://www.grid.ac/institutes/grid.410345.7 schema:Organization
    54 https://www.grid.ac/institutes/grid.410569.f schema:Organization
    55 https://www.grid.ac/institutes/grid.411339.d schema:Organization
    56 https://www.grid.ac/institutes/grid.412914.b schema:Organization
    57 https://www.grid.ac/institutes/grid.412920.c schema:Organization
    58 https://www.grid.ac/institutes/grid.413396.a schema:Organization
    59 https://www.grid.ac/institutes/grid.413449.f schema:Organization
    60 https://www.grid.ac/institutes/grid.413964.d schema:Organization
    61 https://www.grid.ac/institutes/grid.415172.4 schema:Organization
    62 https://www.grid.ac/institutes/grid.415490.d schema:Organization
    63 https://www.grid.ac/institutes/grid.415598.4 schema:Organization
    64 https://www.grid.ac/institutes/grid.415970.e schema:Organization
    65 https://www.grid.ac/institutes/grid.417068.c schema:Organization
    66 https://www.grid.ac/institutes/grid.417581.e schema:Organization
    67 https://www.grid.ac/institutes/grid.417893.0 schema:Organization
    68 https://www.grid.ac/institutes/grid.419248.2 schema:Organization
    69 https://www.grid.ac/institutes/grid.419319.7 schema:Organization
    70 https://www.grid.ac/institutes/grid.426108.9 schema:Organization
    71 https://www.grid.ac/institutes/grid.439749.4 schema:Organization
    72 https://www.grid.ac/institutes/grid.4563.4 schema:Organization
    73 https://www.grid.ac/institutes/grid.459389.a schema:Organization
    74 https://www.grid.ac/institutes/grid.475435.4 schema:Organization
    75 https://www.grid.ac/institutes/grid.5600.3 schema:Organization
    76 https://www.grid.ac/institutes/grid.5645.2 schema:Organization
    77 https://www.grid.ac/institutes/grid.6292.f schema:Organization
    78 https://www.grid.ac/institutes/grid.7700.0 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...